Are Asthma-COPD Overlap Syndrome Patients Receiving Optimal Therapy?

Researchers used data from a large clinical practice to evaluate patients with ACOS and their Tx regimen
Researchers used data from a large clinical practice to evaluate patients with ACOS and their Tx regimen

A new retrospective study reveals more details about the treatment regimens of patients with asthma and chronic obstructive pulmonary disease overlap syndrome (ACOS), for which there is limited medical guidance.

The researchers used data from a large, academic clinical practice that serves a large urban area and its surrounding rural community. Their objective was to evaluate a patient population with possible ACOS and their regimen based on the Global Initiative for Asthma and Global Initiative for COPD joint statement for ACOS. The sample included a total of 513 patients aged 40 to 85 years old (61 years mean age; 75% female) with an active concurrent diagnosis of asthma and COPD. 

Related Articles

The results showed that 85% of ACOS patients were prescribed both preventive and rescue medicine (defined as consistent therapy), while 7% were prescribed preventive medication but no rescue medication (likely inconsistent therapy), and 7.7% were prescribed neither preventive nor rescue medication (inconsistent therapy).

Never smokers were more likely than former smokers to be in the inconsistent therapy group, relative to being in the likely consistent therapy group (adjusted OR, 4.54; CI, 1.86-11.04). Older adults (≥65 years) were more likely to be in the likely inconsistent therapy group than those aged 40 to 49 years (OR, 4.01; CI, 1.04-15.34), while they found that patients without any comorbid conditions were more likely than those with ≥2 comorbid conditions to be in the likely inconsistent group (adjusted OR = 3.50; CI = 1.39-8.77).

The author's concluded that, “older, nonsmoking, relatively healthier adults were at greater risk for being prescribed suboptimal therapy.” They also suggest as the disease definition of ACOS and it's treatment options evolve, future studies are needed to assess symptoms and therapy to manage this population.

For more information visit Sagepub.com.

Loading links....